Labquality’s international team welcomes you to visit our exhibition booth at ECCMID, which will be held from 27 to 30 April 2024 in Barcelona. Our booth is E5 in the exhibition hall. Labquality proudly promotes external quality assessment services for microbiology and CRO services for pharmaceutical and MD/IVD companies.
Sales Director Juha Wahlstedt, Key Account Manager Jukka Korhonen, and Customer Service Coordinator Teija Häkkinen from the EQA services will be available for discussions during the exhibition hours. To book an appointment, please contact juha.wahlstedt@labquality.com.
Tadeusz Baron, Managing Director of our Polish CRO company, Quality and Regulatory Affairs Manager Katja Eronen, and Sales Director Meeri Säily will represent our CRO and regulatory affairs services and look forward to discussing clinical research and regulatory questions.
The microbiological EQA programs are suitable for clinical laboratories and POCT sites performing testing in bacterial serology, bacteriology, mycology, parasitology, virology, and preanalytics for microbiology. While the selection includes schemes for antigen detection, antibody detection, culture, microscopy, MALDI-TOF, multiplex methods, and PCR tests, solutions for versatile needs are available. Authentic single-donor samples are included in multiple schemes. Over 8000 laboratories worldwide have chosen Labquality as their primary EQA provider.
We are continuously looking for new distributors for our EQA service. Labquality’s distributor network covers Europe, the Middle East, Southeast Asia, South America, and the US. If you already have some experience in distributing external quality assessment services (proficiency testing programs) and are looking for an international EQA provider, you are very welcome to book an appointment with us. Please contact sales director Juha Wahlstedt at juha.wahlstedt@labquality.fi.
Welcome to learn more about our wide offering of CRO services for pharmaceutical and Medical Device manufacturers. We have considerable experience in working with infectious disease trials, covering, for example, Antibiotic Resistance Studies, including but not limited to CAP, HAP, VAP, cUTI, and AP; vaccine trials; and antiviral therapies. We are happy to discuss clinical operations, regulatory affairs, IMP management, and laboratory services.
We also look forward to potential new partnerships and collaborations related to clinical research for In Vitro Diagnostics (IVD) devices, aiming to further their development and accessibility.